The Manila Times

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting ...
ascopubs.org

Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with ...

Novel models for the functional characterization of SDHA germline variants to predict cancer risk. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include ...
ascopubs.org

Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot ...

Impact of age on functional decline following radical nephrectomy: Analysis of the International Marker Consortium for Renal Cancer (INMARC). Background: Hand-foot skin reaction (HFSR) is associated ...
Seeking Alpha

Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript

Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...